The winter flu season has lifted Reckitt Benckiser’s first-quarter sales, with revenue growing by 7% to £2.5bn.
The maker of Dettol, Nurofen and Strepsils today reported like-for-like sales of its health products were up 13%.
“We are pleased with a strong start to the year, with our Health and Hygiene brands leading RB’s growth across all geographies,” said CEO Rakesh Kapoor.
“Mucinex and Strepsils have done particularly well, benefitting from a higher incidence of flu in the US and cold, flu and sinus innovations. Nurofen and Durex also had a strong performance. In Hygiene, Dettol continues to grow very strongly in emerging market areas.”
Reckitt Benckiser said it was on course to meet its full-year targets of 5-6% growth.